5 Results for "

Nsp15

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Nsp15" in MCE Product Catalog:

Cat. No.: HY-105721
CAS No.: 19885-51-9
Target:  

SARS-CoV

Research Areas:  

Infection

Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research .
loading...
    loading...
Cat. No.: HY-171189
CAS No.: 351891-58-2
Target:  

SARS-CoV

Research Areas:  

Infection

C-467929 is an Nsp15 endoribonuclease inhibitor with an IC50 of 8 μM. C-467929 binds to the SARS-CoV Nsp15 protein and can be utilized in infection research .
loading...
    loading...
Cat. No.: HY-162956
CAS No.: 364338-71-6
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-97 (Compound CO-01) is an inhibitor for SARS-CoV-2 Nsp15 endoribonuclease with an IC50 of 53.5 μM. SARS-CoV-2-IN-97 exhibits low cytotoxicity in A549-AT cell with IC50 of 134 μM .
loading...
    loading...
Cat. No.: HY-183761
Research Areas:  

Infection

Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Kd value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections .
loading...
    loading...
Cat. No.: HY-L052
1,379 compounds

COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.

Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1,379 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.